Cryptococcosis by Cryptococcus gattii is endemic in Colombia, affecting mostly immunocompetent hosts. Since antifungal susceptibility differs between molecular types of cryptococcal isolates, as reported elsewhere, the aim of this study was to determine if 42 Colombian clinical isolates, VGI, VGII and VGIII, differ in the susceptibility to commonly used antifungals, using Sensititre plates. Among the molecular types, six non-wild type isolates to fluconazole, voriconazole and 5-flucytosine, were identified. Besides, VGI and VGII were less susceptible to 5-flucytosine and azoles, respectively, than other molecular types. These findings support the applicability of practicing susceptibility testing, which could better guide treatment in cryptococcosis.
|Original language||English (US)|
|Number of pages||1125|
|Early online date||Jul 15 2021|
|State||Published - Nov 2021|
|Event||Congress on Trends in Medical Mycology - Aberdeen, United Kingdom|
Duration: Oct 8 2021 → Oct 11 2021
Conference number: 10th